Association Between Multiparametric Magnetic Resonance Imaging of the Prostate and Oncological Outcomes after Primary Treatment for Prostate Cancer: A Systematic Review and Meta-analysis
- PMID: 33384275
- DOI: 10.1016/j.euo.2020.11.008
Association Between Multiparametric Magnetic Resonance Imaging of the Prostate and Oncological Outcomes after Primary Treatment for Prostate Cancer: A Systematic Review and Meta-analysis
Abstract
Context: The diagnostic accuracy of multiparametric magnetic resonance imaging (mpMRI) for prostate cancer (PCa) diagnosis has been extensively explored. Little is known about the prognostic value of mpMRI suspicion scores and other quantitative mpMRI information.
Objective: To systematically review the current literature assessing the relationship between pretreatment mpMRI and oncological outcomes after primary treatment for PCa to assess the role of mpMRI as a prognostic tool.
Evidence acquisition: A computerized bibliographic search of MEDLINE/PubMed, EMBASE, Scopus, and the Cochrane Library CENTRAL databases was performed for all studies assessing the relationship between mpMRI and oncological outcomes after primary treatment for PCa. The review protocol is registered in the PROSPERO database (CRD42020209899).
Evidence synthesis: A total of six studies were included. Reliable evidence is still limited in this field. The Prostate Imaging-Reporting and Data System (PI-RADS) score was an independent predictor of biochemical recurrence (BCR) after radical prostatectomy (RP) in the majority of the studies included. The tumor volume at mpMRI was not significantly associated with BCR after RP for PCa. Data on disease progression and PCa-specific mortality are limited. Heterogeneity among the studies was substantial.
Conclusions: The review shows that PI-RADS scores provide information on the future likelihood of cancer recurrence or progression, at least for men undergoing RP. We are of the view that this information should be taken into account to identify men at higher risk of unfavorable outcomes.
Patient summary: A higher Prostate Imaging-Reporting and Data System score for magnetic resonance imaging of the prostate seems to be positively associated with oncological failure in prostate cancer and should be incorporated into future risk models.
Keywords: Multiparametric magnetic resonance imaging; Oncological outcomes; Prognosis; Prostate cancer.
Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Comment in
-
Can Diagnostic Magnetic Resonance Imaging for Suspected Clinically Significant Prostate Cancer Predict Unfavorable Long-term Outcome for Diagnosed Men for Pretreatment Counseling?Eur Urol Oncol. 2021 Aug;4(4):529-531. doi: 10.1016/j.euo.2020.12.014. Epub 2021 Jan 18. Eur Urol Oncol. 2021. PMID: 33478935 No abstract available.
Similar articles
-
Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.Eur Urol Oncol. 2020 Dec;3(6):739-747. doi: 10.1016/j.euo.2020.07.008. Epub 2020 Aug 23. Eur Urol Oncol. 2020. PMID: 32847747
-
Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis.Eur Urol Oncol. 2021 Oct;4(5):697-713. doi: 10.1016/j.euo.2020.12.004. Epub 2020 Dec 25. Eur Urol Oncol. 2021. PMID: 33358543
-
Magnetic Resonance Imaging-based T-staging to Predict Biochemical Recurrence after Radical Prostatectomy: A Step Towards the iTNM Classification.Eur Urol Oncol. 2023 Aug;6(4):406-413. doi: 10.1016/j.euo.2022.09.005. Epub 2022 Oct 21. Eur Urol Oncol. 2023. PMID: 36280445
-
Multiparametric Magnetic Resonance Imaging Is an Independent Predictor of Salvage Radiotherapy Outcomes After Radical Prostatectomy.Eur Urol. 2018 Jun;73(6):879-887. doi: 10.1016/j.eururo.2017.11.012. Epub 2017 Nov 28. Eur Urol. 2018. PMID: 29195777
-
The prognostic role of prostate MRI in prostate cancer patients.Curr Opin Urol. 2025 Jul 1;35(4):418-425. doi: 10.1097/MOU.0000000000001288. Epub 2025 Apr 23. Curr Opin Urol. 2025. PMID: 40269557 Review.
Cited by
-
MRI lesion size is more important than the number of positive biopsy cores in predicting adverse features and recurrence after radical prostatectomy: implications for active surveillance criteria in intermediate-risk patients.Prostate Cancer Prostatic Dis. 2024 Jun;27(2):318-322. doi: 10.1038/s41391-023-00693-z. Epub 2023 Jul 14. Prostate Cancer Prostatic Dis. 2024. PMID: 37452146
-
Optimizing clinical risk stratification of localized prostate cancer.Curr Opin Urol. 2025 Jul 1;35(4):426-431. doi: 10.1097/MOU.0000000000001294. Epub 2025 May 2. Curr Opin Urol. 2025. PMID: 40314071 Free PMC article. Review.
-
MRI-Detectability of Clinically Significant Prostate Cancer Relates to Oncologic Outcomes After Prostatectomy.Clin Genitourin Cancer. 2022 Aug;20(4):319-325. doi: 10.1016/j.clgc.2022.04.001. Epub 2022 Apr 14. Clin Genitourin Cancer. 2022. PMID: 35618599 Free PMC article.
-
PI-RADS: Where Next?Radiology. 2023 Jun;307(5):e223128. doi: 10.1148/radiol.223128. Epub 2023 Apr 25. Radiology. 2023. PMID: 37097134 Free PMC article. Review.
-
Oncological outcomes after radical prostatectomy of localized prostate cancer: stratified by magnetic resonance imaging and risk classification.Prostate Int. 2024 Dec;12(4):224-230. doi: 10.1016/j.prnil.2024.09.003. Epub 2024 Sep 28. Prostate Int. 2024. PMID: 39735202 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous